New drug trial aims to protect young brains from sickle cell damage
NCT ID NCT05725902
Summary
This study is testing if a drug called etavopivat can improve blood flow and oxygen delivery to the brain in children and young adults with sickle cell disease. It will involve about 12 participants aged 12 to 21 who will take the drug for 24 weeks. Researchers will use special light-based scans to measure changes in brain blood flow before, during, and after treatment to see if the drug helps.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University Children's Healthcare of Atlanta
Atlanta, Georgia, 30342, United States
Conditions
Explore the condition pages connected to this study.